Terns Pharmaceuticals, Inc.
TERN
Classement en actions
#3584
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Prix de l'action
$52.95
Dernière synchronisation: 2026-05-15
Capitalisation boursière
$4.77B
Changement (1 jour)
0.00%
Changement (1 an)
529.61%
Pays
US
Échange Terns Pharmaceuticals, Inc. (TERN)
Catégorie
Healthcare
EPS pour Terns Pharmaceuticals, Inc. (TERN)
EPS au December 2025 TTM : $-1.03
Selon les derniers rapports financiers et le cours de l'action de Terns Pharmaceuticals, Inc., l’EPS actuel de la société (TTM) est de $-1.03. À la fin de 2023, la société avait un EPS de $-1.27 une diminution par rapport à celui de 2022, qui était de $-1.67.
Historique de l'EPS de Terns Pharmaceuticals, Inc. de 2018 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-1.03 | -8.04% |
| 2024 | $-1.12 | -11.81% |
| 2023 | $-1.27 | -23.95% |
| 2022 | $-1.67 | -15.66% |
| 2021 | $-1.98 | 22.98% |
| 2020 | $-1.61 | -41.24% |
| 2019 | $-2.74 | 270.27% |
| 2018 | $-0.74 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -1,781.55% |
US
|
|
| $-7.98 | 674.76% |
US
|
|
| $-5.29 | 413.59% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,793.20% |
NL
|
